PAS
FATE icon

Point72 Asia (Singapore)’s Fate Therapeutics FATE Stock Holding History

Point72 Asia (Singapore)’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50
Closed -$56 – 1016
2025
Q2 		$56 Buy
+50
New +$58 ﹤0.01% 838
2025
Q1 		– Sell
-33,094
Closed -$54.6K – 979
2024
Q4 		$54.6K Buy
+33,094
New +$83.4K 0.01% 492
2024
Q1 		– Sell
-14,805
Closed -$55.4K – 1118
2023
Q4 		$55.4K Buy
+14,805
New +$34.9K 0.01% 291

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wilshire Advisors Santa Monica, California $10.3M AUM 79.91% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Point72 Asia (Singapore)'s FATE Position: Q3 2025 in Review

Point72 Asia (Singapore) sold out of Fate Therapeutics (FATE) in Q3 2025, closing a stake of 50 shares — an estimated $56 sold.

Point72 Asia (Singapore) first reported a position in FATE in Q4 2023 and held it in 3 quarters. The position peaked at $55.4K in Q4 2023. 143 funds tracked by Wall St. Rank hold FATE as of Q3 2025.

  • Point72 Asia (Singapore) reported no remaining Fate Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 50 Fate Therapeutics shares in Q3 2025, an estimated $56.
  • Point72 Asia (Singapore) first reported a position in Fate Therapeutics in Q4 2023 and held it in 3 quarters.
  • Point72 Asia (Singapore)'s Fate Therapeutics position peaked at $55.4K in Q4 2023.
  • 143 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.